LIVIVO - Search results -

Search results

Result 1 - 10 of total 14

Search options

Article ; Online: Interferon: The invisible link in the physiopathology of COVID-19 and BCGitis?

Di Bella, Stefano / Cabas, Paolo / Antonello, Roberta Maria / Rizzo, Michele

2020 Volume 92, Issue 6, Page(s) e12939

MeSH term(s)	BCG Vaccine/immunology ; COVID-19/immunology ; Female ; Humans ; Inflammation/immunology ; Interferon-gamma/metabolism ; Male ; Mycobacterium tuberculosis/physiology ; SARS-CoV-2/physiology ; Sex Characteristics ; Sex Factors ; Signal Transduction ; Th1 Cells/immunology ; Tuberculosis/immunology ; Vaccination
Chemical Substances	BCG Vaccine ; Interferon-gamma (82115-62-6)
Keywords	covid19
Language	English
Publishing date	2020-08-04
Publishing country	England
Document type	Letter
ZDB-ID	120476-2
ISSN	1365-3083 ; 0300-9475
ISSN (online)	1365-3083
ISSN	0300-9475
DOI	10.1111/sji.12939
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 806: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾

Article: Humoral and T-Cell Mediated Response after the Third Dose of mRNA Vaccines in Patients with Systemic Lupus Erythematosus on Belimumab.

Quartuccio, Luca / De Marchi, Ginevra / Domenis, Rossana / Cabas, Nicola / Guella, Silvia / Paradiso, Antonella / Fabro, Cinzia / Beltrami, Antonio Paolo / De Vita, Salvatore / Curcio, Francesco

Journal of clinical medicine

2023 Volume 12, Issue 3

Abstract: Objective: To evaluate humoral and T-cell cellular-mediated immune response after three doses of SARS-CoV-2 mRNA vaccines in patients with systemic lupus erythematosus (SLE) under Belimumab.: Patients and methods: 12 patients on Belimumab and 13 age- ... ...

Abstract	Objective: To evaluate humoral and T-cell cellular-mediated immune response after three doses of SARS-CoV-2 mRNA vaccines in patients with systemic lupus erythematosus (SLE) under Belimumab. Patients and methods: 12 patients on Belimumab and 13 age-matched healthy volunteers were recruited. Patients were in remission or in low disease activity, and they were taking no corticosteroids or only low doses. None of the patients and controls had detectable anti-SARS-CoV-2 antibodies due to previous exposure to the virus. All the patients received three doses of mRNA anti-SARS-CoV-2 vaccines and the humoral and cellular-mediated response were tested 4 weeks after the second dose (T0), 6 months after the second dose (T1) and 4 weeks after the third dose (T2). Comparison with the control group was performed at time T0 (i.e., 4 weeks after the second dose). Total anti-SARS-CoV-2 RBD antibodies were analyzed using a diagnostic assay, while cellular-mediated response was evaluated using the interferon-gamma release assay (IGRA). Results: A humoral response was documented in all the patients at T0 (median 459; IQR 225.25-758.5), but the antibody titer significantly declined from T0 to T1 (median 44.7; IQR: 30.3-202; Conclusion: The third dose of mRNA COVID-19 vaccine can restore both humoral and cellular immune response in SLE patients on Belimumab.
Language	English
Publishing date	2023-01-30
Publishing country	Switzerland
Document type	Journal Article
ZDB-ID	2662592-1
ISSN	2077-0383
ISSN	2077-0383
DOI	10.3390/jcm12031083
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article: Interferon: The invisible link in the physiopathology of COVID-19 and BCGitis?

Di Bella, Stefano / Cabas, Paolo / Antonello, Roberta Maria / Rizzo, Michele

Scand J Immunol

Keywords	covid19
Publisher	WHO
Document type	Article
Note	WHO #Covidence: #700279
Database	COVID19

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Details ▾

Article ; Online: Interferon

Di Bella, Stefano / Cabas, Paolo / Antonello, Roberta Maria / Rizzo, Michele

Scandinavian Journal of Immunology ; ISSN 0300-9475 1365-3083

The invisible link in the physiopathology of COVID‐19 and BCGitis?

2020

Keywords	Immunology ; General Medicine ; covid19
Language	English
Publisher	Wiley
Publishing country	us
Document type	Article ; Online
DOI	10.1111/sji.12939
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Needle tract seeding after percutaneous cryoablation of small renal masses; a case series and literature review.

Rizzo, Michele / Cabas, Paolo / Pavan, Nicola / Umari, Paolo / Verzotti, Enrica / Boltri, Matteo / Stacul, Fulvio / Bertolotto, Michele / Liguori, Giovanni / Trombetta, Carlo

Scandinavian journal of urology

2020 Volume 54, Issue 2, Page(s) 122–127

Abstract: Neoplastic cell seeding due to needle tumor manipulation during renal mass biopsy (RMB) or thermal ablative treatment is a rare but potentially serious event that can turn an organ-confined and curable tumor in a nonorgan-confined and non-curable disease. ...

Abstract	Neoplastic cell seeding due to needle tumor manipulation during renal mass biopsy (RMB) or thermal ablative treatment is a rare but potentially serious event that can turn an organ-confined and curable tumor in a nonorgan-confined and non-curable disease. Despite the widespread use of percutaneous thermal ablative treatment for small renal masses (SRMs), this complication has been described in few case reports and small case series and has never been reported after ablative treatment alone. We report a series of two patients that underwent cryoablation for SRMs and developed recurrence along the needle tract. Available knowledge on the controversial topic of tumor seeding following needle manipulation are poor. So far, reporting cases of tumor cell seeding due to needle manipulation is useful to permit a better understanding of this complication.
MeSH term(s)	Aged ; Carcinoma, Renal Cell/secondary ; Carcinoma, Renal Cell/surgery ; Cryosurgery/adverse effects ; Cryosurgery/instrumentation ; Cryosurgery/methods ; Humans ; Kidney Neoplasms/pathology ; Kidney Neoplasms/surgery ; Male ; Middle Aged ; Needles ; Neoplasm Seeding ; Nephrectomy/methods ; Tumor Burden
Language	English
Publishing date	2020-03-10
Publishing country	England
Document type	Case Reports ; Journal Article ; Review
ZDB-ID	2701936-6
ISSN	2168-1813 ; 2168-1805
ISSN (online)	2168-1813
ISSN	2168-1805
DOI	10.1080/21681805.2020.1736149
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 601: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Humoral and T-Cell Mediated Response after the Third Dose of mRNA Vaccines in Patients with Systemic Lupus Erythematosus on Belimumab

Luca Quartuccio / Ginevra De Marchi / Rossana Domenis / Nicola Cabas / Silvia Guella / Antonella Paradiso / Cinzia Fabro / Antonio Paolo Beltrami / Salvatore De Vita / Francesco Curcio

Journal of Clinical Medicine, Vol 12, Iss 1083, p

2023 Volume 1083

Abstract: Objective: To evaluate humoral and T-cell cellular-mediated immune response after three doses of SARS-CoV-2 mRNA vaccines in patients with systemic lupus erythematosus (SLE) under Belimumab. Patients and methods: 12 patients on Belimumab and 13 age- ... ...

Abstract	Objective: To evaluate humoral and T-cell cellular-mediated immune response after three doses of SARS-CoV-2 mRNA vaccines in patients with systemic lupus erythematosus (SLE) under Belimumab. Patients and methods: 12 patients on Belimumab and 13 age-matched healthy volunteers were recruited. Patients were in remission or in low disease activity, and they were taking no corticosteroids or only low doses. None of the patients and controls had detectable anti-SARS-CoV-2 antibodies due to previous exposure to the virus. All the patients received three doses of mRNA anti-SARS-CoV-2 vaccines and the humoral and cellular-mediated response were tested 4 weeks after the second dose (T0), 6 months after the second dose (T1) and 4 weeks after the third dose (T2). Comparison with the control group was performed at time T0 (i.e., 4 weeks after the second dose). Total anti-SARS-CoV-2 RBD antibodies were analyzed using a diagnostic assay, while cellular-mediated response was evaluated using the interferon-gamma release assay (IGRA). Results: A humoral response was documented in all the patients at T0 (median 459; IQR 225.25–758.5), but the antibody titer significantly declined from T0 to T1 (median 44.7; IQR: 30.3–202; p = 0.0066). At T2, the antibody titer significantly increased from T1 (median 2500; IQR: 2500–2500), and it was not different from T0 (respectively p < 0.0001, p = 0.66). Cellular-mediated response significantly declined from T0 to T1 ( p = 0.003) but not from T0 to T2 ( p = 0.3). No differences were found between patients and controls at T0 as regards both humoral and cellular responses ( p = 1.0 and p = 0.09 for humoral and cellular responses, respectively). Conclusion: The third dose of mRNA COVID-19 vaccine can restore both humoral and cellular immune response in SLE patients on Belimumab.
Keywords	lupus ; belimumab ; vaccine ; coronavirus ; COVID-19 ; immunity ; Medicine ; R
Subject code	610
Language	English
Publishing date	2023-01-01T00:00:00Z
Publisher	MDPI AG
Document type	Article ; Online
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: High T-cell response rate after COVID-19 vaccination in belimumab and rituximab recipients.

Fabris, Martina / De Marchi, Ginevra / Domenis, Rossana / Caponnetto, Federica / Guella, Silvia / Dal Secco, Chiara / Cabas, Nicola / De Vita, Salvatore / Beltrami, Antonio Paolo / Curcio, Francesco / Quartuccio, Luca

Journal of autoimmunity

2022 Volume 129, Page(s) 102827

Abstract: Objective: To evaluate B-cell- and T-cell-mediated immune response to SARS-CoV-2 mRNA vaccination in patients with complex or rare systemic autoimmune diseases previously been treated with or under continuous treatment with B-cell-targeted therapies ... ...

Abstract	Objective: To evaluate B-cell- and T-cell-mediated immune response to SARS-CoV-2 mRNA vaccination in patients with complex or rare systemic autoimmune diseases previously been treated with or under continuous treatment with B-cell-targeted therapies including rituximab (RTX) and belimumab (BEL). Materials and methods: Twenty-eight consecutive patients receiving RTX (n = 11) or BEL (n = 17) treatment and 13 age-/sex-matched controls (non-rheumatic healthcare personnel) were recruited. None of the patients had detectable anti-SARS-CoV-2 antibodies caused by prior exposure to the virus. All the patients and controls received mRNA vaccines and were tested three to four weeks after completion of vaccination. In all the RTX patients, vaccination was started within 5 months from the last infusion, and B-cell depletion was confirmed in all but one of them. Total anti-SARS-CoV-2 RBD antibodies were analyzed using a diagnostic assay, while T-cell response was evaluated using the interferon-gamma release assay (IGRA). Further, SARS-CoV-2 pseudoviruses were employed to verify the strain-specific neutralizing capacity of the antibodies. Results: Detectable anti-SARS-CoV-2 antibodies were documented in 1 out of the 11 RTX patients and 16 of the 17 BEL patients. The median concentration in the RTX and BEL patients was significantly lower than that in the controls (39.6 AU/ml vs. 1133 AU/ml, p = 0.002). The result of IGRA was positive in 8 of the 11 (72.7%) RTX patients and 16 of the 17 (94.1%) BEL patients, and interferon release in both the RTX and BEL patients was comparable to that in the control participants. Conclusion: B-cell-targeted therapies do not preclude SARS-CoV-2 vaccination, since virus-specific cellular immunity can be induced even in the absence of circulating B cells. An important finding was that lupus patients treated with BEL developed immune responses to SARS-CoV-2; this indicates retention of the immunogenicity of the COVID-19 vaccine.
MeSH term(s)	Antibodies, Monoclonal, Humanized ; Antibodies, Viral ; COVID-19 ; COVID-19 Vaccines ; Humans ; Immunity, Cellular ; Rituximab/therapeutic use ; SARS-CoV-2 ; T-Lymphocytes ; Vaccination
Chemical Substances	Antibodies, Monoclonal, Humanized ; Antibodies, Viral ; COVID-19 Vaccines ; Rituximab (4F4X42SYQ6) ; belimumab (73B0K5S26A)
Language	English
Publishing date	2022-04-11
Publishing country	England
Document type	Journal Article
ZDB-ID	639452-8
ISSN	1095-9157 ; 0896-8411
ISSN (online)	1095-9157
ISSN	0896-8411
DOI	10.1016/j.jaut.2022.102827
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 2368: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Community pharmacists' exposure to COVID-19.

Cabas, Paolo / Di Bella, Stefano / Giuffrè, Mauro / Rizzo, Michele / Trombetta, Carlo / Luzzati, Roberto / Antonello, Roberta Maria / Parenzan, Ketty / Liguori, Giovanni

Research in social & administrative pharmacy : RSAP

2020 Volume 17, Issue 1, Page(s) 1882–1887

Abstract: Introduction: Since the beginning of the 2020 Sars-CoV-2 Italian outbreak, healthcare workers have been among the most exposed categories. There is little information about community pharmacists' on occupational exposure, symptoms development, and ... ...

Abstract	Introduction: Since the beginning of the 2020 Sars-CoV-2 Italian outbreak, healthcare workers have been among the most exposed categories. There is little information about community pharmacists' on occupational exposure, symptoms development, and testing practices in the community pharmacist cohort. Methods: Between April 30th and May 10th, a questionnaire was administered through social media to Italian community pharmacists. From 67000 pharmacists currently working in community pharmacies, 1632 answered the survey. Results: The survey population reflected the general Italian community pharmacists population in terms of age, gender, and number of co-workers. Protective measures were adopted in up to 99.9% of pharmacies. 624 pharmacists (38.2%) developed at least one COVID-19 related symptom in the period between February 28th and May 10th. Also, 102 pharmacists (6.2%) were tested for COVID-19 and 15, the 15% of the tested population and 0.92% of the whole survey population, resulted positive on nasopharyngeal swab. However, while the number of symptomatic pharmacists decreased, a higher number of tests were performed, thus COVID-19 prevalence among community pharmacists could have been underestimated and is probably intermediate between other healthcare workers and the general population (0.31%). Conclusion: Community pharmacists have probably been one of the first categories to experience increased contact risk to SARS-CoV-2. COVID-19 prevalence among pharmacists could have been underestimated. In addition, the rates of protection measures adoption might have helped to reduce the spread of COVID-19 among co-workers and the community.
MeSH term(s)	Adult ; COVID-19/diagnosis ; COVID-19/epidemiology ; COVID-19/transmission ; COVID-19 Testing ; Community Pharmacy Services ; Female ; Humans ; Italy ; Male ; Occupational Exposure/statistics & numerical data ; Pharmacists/statistics & numerical data ; Prevalence ; Surveys and Questionnaires
Keywords	covid19
Language	English
Publishing date	2020-05-27
Publishing country	United States
Document type	Journal Article
ZDB-ID	2192059-X
ISSN	1934-8150 ; 1551-7411
ISSN (online)	1934-8150
ISSN	1551-7411
DOI	10.1016/j.sapharm.2020.05.020
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: BCG infection (BCGitis) following intravesical instillation for bladder cancer and time interval between treatment and presentation: A systematic review.

Cabas, Paolo / Rizzo, Michele / Giuffrè, Mauro / Antonello, Roberta Maria / Trombetta, Carlo / Luzzati, Roberto / Liguori, Giovanni / Di Bella, Stefano

Urologic oncology

2020 Volume 39, Issue 2, Page(s) 85–92

Abstract: Objective: Intravesical Bacillus Calmette-Guèrin (BCG) is an effective treatment in non--muscle-invasive bladder cancer, however, extravesical BCG infection may occur in remote organs as a potentially serious complication. Researchers aimed to assess ... ...

Abstract	Objective: Intravesical Bacillus Calmette-Guèrin (BCG) is an effective treatment in non--muscle-invasive bladder cancer, however, extravesical BCG infection may occur in remote organs as a potentially serious complication. Researchers aimed to assess whether a different timing of BCG infection after intravesical administration of BCG could be identified and estimated for each single involved organ. Methods: We performed a systematic literature review over systemic and genitourinary BCG infection case reports, including 271 published case reports for a total of 307 patients. Demographic data, clinical features, and timing of BCG infection development were collected and analyzed for each patient. Results: BCG infection developed with a different timing from last instillation, depending on the involved organ. Among the genitourinary complications, penile lesions occurred as early as 1 (1;3) weeks, while orchiepididymitis occurred as late as 56 (6.25;156) weeks. At the same time, granulomatous hepatitis and lungs involvement such as miliary pulmonary BCG infection occurred earlier, with a median time of 1 (1;4) and 1 (1;6) weeks respectively, whereas vascular, osteoarticular, and muscular complications developed with a median timing from last instillation of 52 (20;104), 68 (14;156), and 93 (29;156) weeks, respectively. The analysis detected a cluster between lungs, liver, and bone marrow complications on one side and muscular and osteoarticular or vascular complications on the other side was also observed. Conclusions: BCG infection after intravesical BCG for bladder cancer may develop even several months or years after the last instillation, depending on the involved organs. When BCG infection interests one or more organ, 2 main associative patterns are common: one involving lungs, liver, and bone marrow, with earlier occurrence but lower rates of microbiological diagnosis achievement, and one involving muscular and osteoarticular or vascular districts, with later occurrence but higher rates of microbiological evidence.
MeSH term(s)	Adjuvants, Immunologic/administration & dosage ; Adjuvants, Immunologic/adverse effects ; Administration, Intravesical ; BCG Vaccine/administration & dosage ; BCG Vaccine/adverse effects ; Humans ; Time Factors ; Tuberculosis/chemically induced ; Urinary Bladder Neoplasms/drug therapy
Chemical Substances	Adjuvants, Immunologic ; BCG Vaccine
Language	English
Publishing date	2020-12-08
Publishing country	United States
Document type	Journal Article ; Systematic Review
ZDB-ID	1336505-8
ISSN	1873-2496 ; 1078-1439
ISSN (online)	1873-2496
ISSN	1078-1439
DOI	10.1016/j.urolonc.2020.11.037
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 4817: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Community pharmacists' exposure to COVID-19

Cabas, Paolo / Di Bella, Stefano / Giuffrè, Mauro / Rizzo, Michele / Trombetta, Carlo / Luzzati, Roberto / Antonello, Roberta Maria / Parenzan, Ketty / Liguori, Giovanni

Research in Social and Administrative Pharmacy ; ISSN 1551-7411

2020

Keywords	Pharmaceutical Science ; Pharmacy ; covid19
Language	English
Publisher	Elsevier BV
Publishing country	us
Document type	Article ; Online
DOI	10.1016/j.sapharm.2020.05.020
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

To top

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Kategorien

Inter-library loan at ZB MED

Full text online

More links

Kategorien

Inter-library loan at ZB MED

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

Inter-library loan at ZB MED

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

Inter-library loan at ZB MED